Literature DB >> 12117017

Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia.

Chumpol Piamsomboon1, Prasart Laothavorn, Sopon Saguanwong, Boonsert Chatlaong, Chanarong Nasawadi, Pravit Tanprasert, Kittika Pongsiri.   

Abstract

OBJECTIVES: The authors sought to evaluate the safety and efficacy of atorvastatin administered every other day in patients with hypercholesterolemia.
BACKGROUND: Statins have efficacy in lowering cholesterol and reducing cardiovascular events but their cost is a major disadvantage. Atorvastatin is the most potent statin and has a long half-life. Therefore, atorvastatin given on alternate days may be reasonable and cost effective, particularly in hypercholesterolemia patients. METHOD AND RESULT: Sixty patients with hypercholesterolemia despite diet therapy were enrolled into the study. They received atorvastatin 10 mg every other day before bedtime. Duration of treatment was 8 weeks. A lipid profile was determined as baseline, at 4 weeks and again at 8 weeks. Atorvastatin every other day significantly reduced total cholesterol (TC), triglyceride (TG), and LDL-c versus baseline. The TC, TG, and LDL-c levels were lower by 23 per cent, 8 per cent, and 30 per cent. Increase in HDL-c level was not statistically significant. Three patients had drug side effects. One patient had increased serum transaminase and one patient had increased serum muscle enzyme. The other one had somnolence.
CONCLUSIONS: In hypercholesterolemia patients, atorvastatin 10 mg every other day is safe and effective in lowering TC, TG, with LDL-c and a slight increase in HDL-c.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117017

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  4 in total

1.  Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia.

Authors:  Canna Jagdish Ghia; Archana Sushil Panda; Linesh R Khobragade; Rajesh Kumar Jha; Gautam S Rambhad
Journal:  J Clin Diagn Res       Date:  2014-03-15

2.  Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake.

Authors:  Tetsadê C B Piermartiri; Samuel Vandresen-Filho; Bruno de Araújo Herculano; Wagner C Martins; Denis Dal'agnolo; Ellen Stroeh; Cristiane Lima Carqueja; Carina R Boeck; Carla I Tasca
Journal:  Neurotox Res       Date:  2009-05-02       Impact factor: 3.911

3.  Treating statin-intolerant patients.

Authors:  Marcello Arca; Giovanni Pigna
Journal:  Diabetes Metab Syndr Obes       Date:  2011-04-28       Impact factor: 3.168

Review 4.  Atorvastatin and cardiovascular risk in the elderly--patient considerations.

Authors:  Subroto Acharjee; Francine K Welty
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.